Login to Your Account

Zealand/Sanofi's Lixisenatide as Effective as Lilly's Byetta

By Nuala Moran

Wednesday, February 9, 2011
LONDON – Zealand Pharma A/S advanced its hopes of delivering the second once-daily glucagon-like peptide-1 agonist (GLP-1) to the market, announcing the results from a Phase III trial comparing its product lixisenatide to exenatide (Byetta), which is administered twice daily.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription